Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparan sulfate is a glycosaminoglycan (GAG) biologic that plays a vital role in maintaining the structural and functional integrity of the vascular endothelium. As a major component of the endothelial glycocalyx, it regulates vascular permeability and prevents excessive leukocyte adhesion. In the context of chronic venous disease (CVD), the glycocalyx is often degraded due to venous hypertension; the administration of exogenous heparan sulfate, such as the CLR-07-23 prolonged-release formulation, aims to replenish this layer. This restoration leads to reduced inflammation, decreased edema, and relief from symptoms like pain and night cramps. Heparan sulfate also interacts with various proteins, including antithrombin III and growth factors, to exert antithrombotic and tissue-repair effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparan sulfate.